Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 17, 2021, Taysha Gene Therapies, Inc. (the "Company") held its 2021 annual meeting of stockholders (the "Annual Meeting"). The stockholders considered two proposals, each of which is described in more detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on April 29, 2021. Of the 37,817,164 shares outstanding as of the record date, 31,297,312 shares, or approximately 82.8%, were present or represented by proxy at the Annual Meeting. Set forth below are the results of the matters submitted for a vote of stockholders at the Annual Meeting.

Proposal No. 1: Election of two nominees to serve as directors until the 2024 annual meeting of stockholders and until their respective successors are elected and qualified. The votes were cast as follows:





                   Name              Votes For    Votes Withheld
                   RA Session II     28,848,893      642,482
                   Paul B. Manning   28,723,149      768,226


Broker Non-Votes: 1,805,937.

Both nominees were elected.

Proposal No. 2: Ratification of the appointment of Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2021. The votes were cast as follows:





                                                 Votes For      Votes Against     Abstained
Ratification of appointment of Deloitte &
Touche LLP                                       31,280,156        17,120            36

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses